Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas

被引：15
|
作者：
Tang, Vivian [1 ]
Lu, Rufei [1 ]
Mirchia, Kanish [1 ]
Van Ziffle, Jessica [1 ,2 ]
Devine, Patrick [1 ,2 ]
Lee, Julieann [1 ]
Phillips, Joanna J. J. [1 ,3 ]
Perry, Arie [1 ,3 ]
Raleigh, David R. R. [3 ,4 ]
Lucas, Calixto-Hope G. [1 ,5 ]
Solomon, David A. A. [1 ]
机构：
[1] Univ Calif San Francisco, Dept Pathol, 513 Parnassus Ave,Hlth Sci West 451, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Clin Canc Genom Lab, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA
[5] Johns Hopkins Univ, Sch Med, Dept Pathol, 1800 Orleans St,Sheikh Zayed Tower Room 2101, Baltimore, MD 21287 USA
来源：
ACTA NEUROPATHOLOGICA | 2023年 / 145卷 / 04期
关键词：
D O I：
10.1007/s00401-023-02544-6
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：497 / 500
页数：4
相关论文
共 50 条
  • [31] CDKN2A/p16 in ependymomas
    Bortolotto, S
    Chiadò-Piat, L
    Cavalla, P
    Bosone, I
    Mauro, A
    Schiffer, D
    JOURNAL OF NEURO-ONCOLOGY, 2001, 54 (01) : 9 - 13
  • [32] Prognostic significance of p16/CDKN2A deletion in pleural mesotheliomas
    Dacic, S.
    Popper, H. H.
    Kothmaier, H.
    Halbwedl, I.
    Morbini, P.
    Murer, B.
    Comin, C. E.
    Galateau-Salle, F.
    Demirag, F.
    Zeren, H.
    Attanoos, R.
    Gibbs, A.
    Cagle, P. T.
    LABORATORY INVESTIGATION, 2008, 88 : 339A - 340A
  • [33] Prognostic significance of p16/CDKN2A deletion in pleural mesotheliomas
    Dacic, S.
    Poppei, H. H.
    Kothmaier, H.
    Halbwedt, I.
    Morbini, P.
    Murer, B.
    Comin, C. E.
    Galateau-Salle, F.
    Demirag, F.
    Zeren, H.
    Allanoos, R.
    Gibbs, A.
    Cagle, P. T.
    MODERN PATHOLOGY, 2008, 21 : 339A - 340A
  • [34] CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma
    Sibin, M. K.
    Bhat, Dhananjaya I.
    Narasingarao, K. V. L.
    Lavanya, Ch.
    Chetan, G. K.
    TUMOR BIOLOGY, 2015, 36 (10) : 7607 - 7614
  • [35] Evaluation of p16 Protein Expression and CDKN2A Deletion in Conventional and Fibrosarcomatous Dermatofibrosarcoma Protuberans
    Siref, Andrew
    Patel, Vatsal
    Reith, John D.
    Balzer, Bonnie
    Shon, Wonwoo
    LABORATORY INVESTIGATION, 2017, 97 : 136A - 136A
  • [36] Evaluation of p16 Protein Expression and CDKN2A Deletion in Conventional and Fibrosarcomatous Dermatofibrosarcoma Protuberans
    Siref, Andrew
    Patel, Vatsal
    Reith, John D.
    Balzer, Bonnie
    Shon, Wonwoo
    MODERN PATHOLOGY, 2017, 30 : 136A - 136A
  • [37] Evaluation of p16 protein expression and CDKN2A deletion in conventional and fibrosarcomatous dermatofibrosarcoma protuberans
    Siref, Andrew
    Patel, Vatsal
    Reith, John D.
    Balzer, Bonnie L.
    Shon, Wonwoo
    PATHOLOGY, 2018, 50 (04) : 474 - 475
  • [38] Small Deletions but not Methylation Underlie CDKN2A/p16 Loss of Expression in Conventional Osteosarcoma
    Mohseny, Alexander B.
    Tieken, Chris
    van der Velden, Pieter A.
    Szuhai, Karoly
    de Andrea, Carlos
    Hogendoorn, Pancras C. W.
    Cleton-Jansen, Anne-Marie
    GENES CHROMOSOMES & CANCER, 2010, 49 (12): : 1095 - 1103
  • [39] p16 Immunohistochemistry as a Screening Tool for Homozygous CDKN2A Deletions in CNS Tumors
    Zschernack, Valentina
    Andreiuolo, Felipe
    Doerner, Evelyn
    Wiedey, Anna
    Juenger, Stephanie T.
    Friker, Lea L.
    Maruccia, Riccardo
    Pietsch, Torsten
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2024, 48 (01) : 46 - 53
  • [40] Homozygous deletion of the p16 gene in malignant glioma
    Izumoto, S
    Arita, N
    Ohnishi, T
    Hiraga, S
    Taki, T
    Hayakawa, T
    BRAIN TUMOR: RESEARCH AND THERAPY, 1996, : 263 - 268
12345